Search research articles
Contact Us
Filters
Showing results (611-620 of 742) with videos related to
Page
of 75
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Cancer Medicine
|
March 11, 2015
Complex renal cysts associated with crizotinib treatment
Patrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
The Science of the Total Environment
|
June 1, 2019
A baseline of atmospheric greenhouse gases for prospective UK shale gas sites
Jacob T Shaw, Grant Allen, Joseph Pitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.
ACS Medicinal Chemistry Letters
|
March 28, 2015
Synthesis and Evaluation of Quinazolines as Inhibitors of the Bacterial Cell Division Protein FtsZ
Gabriella M Nepomuceno, Katie M Chan, Valerie Huynh, et al.
Frontiers in Oncology
|
July 11, 2025
Young lung cancer: from diagnosis to survivorship
Narjust Florez, Lauren Kiel, Rebekah Kaufman, et al.
The Lancet. Oncology
|
October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity
Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Page
of 75
Search research articles
Search
Showing results (611-620 of 742) with videos related to
Sort By:
Page
of 75
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2017
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, et al.
Cancer Medicine
|
March 11, 2015
Complex renal cysts associated with crizotinib treatment
Patrick Schnell, Cynthia H Bartlett, Benjamin J Solomon, et al.
The Science of the Total Environment
|
June 1, 2019
A baseline of atmospheric greenhouse gases for prospective UK shale gas sites
Jacob T Shaw, Grant Allen, Joseph Pitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2016
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, et al.
ACS Medicinal Chemistry Letters
|
March 28, 2015
Synthesis and Evaluation of Quinazolines as Inhibitors of the Bacterial Cell Division Protein FtsZ
Gabriella M Nepomuceno, Katie M Chan, Valerie Huynh, et al.
Frontiers in Oncology
|
July 11, 2025
Young lung cancer: from diagnosis to survivorship
Narjust Florez, Lauren Kiel, Rebekah Kaufman, et al.
The Lancet. Oncology
|
October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity
Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Page
of 75